Firm Marks First Annual Assembly at Historic Perkins Place Workplace Constructing as It Prepares to Relocate Its Headquarters from First Horizon Plaza Tower
KNOXVILLE, Tenn., April 20, 2026 (GLOBE NEWSWIRE) — Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) at the moment introduced that it’s going to maintain its 2026 Annual Assembly of Stockholders on Thursday, June 18, 2026, starting at 4:00 p.m. Japanese Time, on the Perkins Place Workplace Constructing (“Perkins Place”), 525 Portland Avenue, Knoxville, Tennessee 37919.
Perkins Place is Provectus’s deliberate new headquarters. The Firm intends to relocate from its present places of work at 800 S. Homosexual Avenue, Suite 1610 (First Horizon Plaza Tower) to Perkins Place in 2026. Holding this 12 months’s Annual Assembly on the new location marks the primary stockholder gathering at what Provectus expects to change into its everlasting operational residence.
A Constructing with Historical past and Strategic Alignment
Designed by Barber & McMurray Architects and opened in 1927 as Perkins Elementary Faculty, Perkins Place was named in honor of Angie Villette Warren Perkins, the primary girl elected to the Knoxville Board of Training and the primary girl in Tennessee to function president of a public-school board, when she was elected president of the Knoxville board in 1918. The constructing is a 22,941 sq. foot construction on a campus on 3.23 acres, absolutely renovated, with ample parking and enough land for future growth.
More Read
Perkins Place carries a direct connection to Ed Pershing, Provectus’s Chairman and Chief Govt Officer. He first encountered the constructing in 1991, when he envisioned it as the long run residence of Pershing Yoakley & Associates (“PYA”), the nationwide healthcare consulting and accounting agency he co-founded in 1983. PYA acquired and restored the constructing in 1992, preserving its interval structure and changing it into a particular company headquarters and presence. PYA occupied Perkins Place till 2009, when PYA’s development demanded it double its workplace house. Within the fall of 2025, Mr. Pershing reacquired the property via a partnership with the East Tennessee Basis that independently sought the constructing for its personal everlasting residence. The association secured a headquarters for Provectus and supplied the Basis with a minority possession curiosity and a long-term headquarters.
Provectus’s deliberate relocation will present the Firm a pathway to successfully handle prices because it grows and provides sources. Extra land and versatile zoning create optionality for future facility improvement, together with the potential for devoted analysis, operational, and/or logistics-adjacent house.
Mr. Pershing mentioned, “Holding our 2026 Annual Meeting of Stockholders at Perkins Place is the right setting for this moment. The building’s history reflects values we recognize in ourselves: vision applied to overlooked assets, perseverance, and outcomes others considered improbable. Provectus’s proprietary synthetic small molecule Rose Bengal Sodium is a molecule being systematically recognized and developed across oncology, dermatology, ophthalmology, and beyond. Perkins Place was not a new building when PYA first claimed it. In both cases, the value was already there. The work was to see it, commit to it, and build. We are planning to do that again at Provectus. Perkins Place is evidence of our expanding vision for Provectus”.
More Read
About Provectus
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology firm creating a pipeline of immunotherapy medicines based mostly on rose bengal sodium, a first-in-class artificial small molecule from the halogenated xanthene household. The Firm’s medical applications span oncology, dermatology, and ophthalmology, with extra proof-of-concept applications in hematology, wound therapeutic, infectious ailments, and tissue restore.
For extra info, go to www.provectusbio.com.
Ahead Wanting Statements
The data on this press launch could embrace “forward-looking statements,” throughout the that means of the Non-public Securities Litigation Reform Act of 1995, referring to the enterprise of Provectus and its associates, that are based mostly on presently accessible info and present assumptions, expectations, and projections about future occasions and are topic to a wide range of dangers and uncertainties and different elements that would trigger precise occasions or outcomes to vary materially from these projected within the forward-looking statements. Ahead-looking statements are sometimes, however not all the time, recognized by way of phrases equivalent to “aim,” “likely,” “outlook,” “seek,” “anticipate,” “budget,” “plan,” “continue,” “estimate,” “expect,” “forecast,” “may,” “will,” “would,” “project,” “projection,” “predict,” “potential,” “targeting,” “intend,” “can,” “could,” “might,” “should,” “believe,” and comparable phrases suggesting future outcomes or statements relating to an outlook.
The protection and efficacy of the brokers and/or makes use of underneath investigation haven’t been established. There isn’t any assure that the brokers will obtain well being authority approval or change into commercially accessible in any nation for the makes use of being investigated or that such brokers as merchandise will obtain any explicit income ranges.
More Read
As a result of dangers, uncertainties, and assumptions inherent in forward-looking statements, readers shouldn’t place undue reliance on these forward-looking statements. The forward-looking statements contained on this press launch are made as of the date hereof or as of the date particularly specified herein, and Provectus undertakes no obligation to replace or revise any forward-looking statements, whether or not on account of new info, future occasions or in any other case, besides in accordance with relevant securities legal guidelines. The forward-looking statements are expressly certified by this cautionary assertion.
Dangers, uncertainties, and assumptions embrace these mentioned within the Firm’s filings with the Securities and Alternate Fee (“SEC”), together with these described in Merchandise 1A of the Firm’s Annual Report on Kind 10-Okay for the interval ended December 31, 2025.
Extra Info and The place to Discover It
Stockholders are urged to learn the definitive proxy assertion when it turns into accessible, as a result of it’s going to include vital details about the Firm and the 2026 Annual Assembly proposals.
This press launch shouldn’t be a proxy assertion or solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the 2026 Annual Assembly proposals. STOCKHOLDERS ARE URGED TO READ CAREFULLY AND, IN ITS ENTIRETY, THE PRELIMINARY PROXY STATEMENT FILED WITH THE SEC AND, WHEN THEY BECOME AVAILABLE, THE DEFINITIVE PROXY STATEMENT AND OTHER RELEVANT MATERIALS, BECAUSE THEY DO AND WILL CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY AND THE 2026 ANNUAL MEETING PROPOSALS. A discover of web availability of proxy supplies with directions for accessing the definitive proxy assertion might be mailed to stockholders as of the document date of April 20, 2026. Stockholders could get hold of free copies of the Firm’s preliminary proxy assertion and its different SEC filings electronically by accessing the SEC’s residence web page at http://www.sec.gov. Copies may also be obtained, freed from cost, upon written request to Provectus Biopharmaceuticals, Inc., Attn: Secretary, 800 S Homosexual St, Suite 1610, Knoxville, Tennessee 37929, (866) 594-5999.
Contributors in Solicitation
This press launch could represent soliciting materials underneath SEC Rule 14a-12, and the Firm and its administrators, government officers, and advisors could also be deemed to be contributors within the solicitation of proxies from the holders of the Firm’s widespread inventory, Collection D Convertible Most well-liked Inventory, and Collection D-1 Convertible Most well-liked Inventory in respect of the 2026 Annual Assembly proposals.
Traders could get hold of extra info relating to the curiosity of these contributors by studying the “Stock Ownership,” “Proposal 1 Election of Directors,” and “Certain Relationships and Related Transactions” sections of the Firm’s preliminary proxy assertion filed with the SEC on April 20, 2026 and, once they change into accessible, the Firm’s definitive proxy assertion and different related proxy supplies, and the Firm’s annual report on Kind 10-Okay for the 12 months ended December 31, 2025, as filed with the SEC on March 26, 2026, and quarterly stories on Kind 10-Q, as filed with the SEC.
